Abstract
Colorectal cancer (CRC) is the second leading cause of cancer death in the United States, and research advances over the past 20 years have allowed us to better understand the molecular mechanisms underlying both tumorigenesis and resistance to therapy. As a result, there are a wide range of novel agents currently under development that we anticipate will enter the clinical arena within the coming years. This review seeks to discuss a spectrum of key pathways and agents that may be particularly relevant to the treatment of CRC in the near future, as well as briefly discuss some of the challenges we face in this new era of drug discovery.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
